Shepelevtseva N G, Vinogradova I V, Shevniuk L A
Antibiot Khimioter. 1990 Nov;35(11):21-4.
Chemotherapeutic efficacy of eremomycin in combination with tobramycin was investigated on a model of experimental sepsis of albino mice caused by Staphylococcus aureus cultures resistant to methicillin. Eremomycin is a novel original antibiotic of the glycopeptide structure isolated in the USSR and tobramycin is an aminoglycoside. Acute toxicity of the combination with a wide range of the dose fixed proportions was studied on mice and the nephrotoxic action of the antibiotics and their combinations administered intravenously for 5 days was studied on albino rats. The experiments showed that the chemotherapeutic effect of eremomycin in combination with tobramycin was of synergistic nature. Acute toxicity of the combined drugs mainly summed up and somewhat increased when the proportion of tobramycin and eremomycin was 1:2.4 or 1:3.6. Eremomycin had a dose-depended nephrotoxicity. Summing up of the nephrotoxic action of the drugs on their combined use was observed.
研究了埃瑞霉素与妥布霉素联合使用对由耐甲氧西林金黄色葡萄球菌培养物引起的白化小鼠实验性败血症模型的化疗效果。埃瑞霉素是苏联分离出的一种新型糖肽结构的原创抗生素,妥布霉素是一种氨基糖苷类抗生素。在小鼠身上研究了固定剂量比例范围的联合用药的急性毒性,并在白化大鼠身上研究了静脉注射5天的抗生素及其联合用药的肾毒性作用。实验表明,埃瑞霉素与妥布霉素联合使用的化疗效果具有协同性质。当妥布霉素与埃瑞霉素的比例为1:2.4或1:3.6时,联合用药的急性毒性主要是相加的,且略有增加。埃瑞霉素具有剂量依赖性肾毒性。观察到药物联合使用时肾毒性作用的相加。